Hepatitis B Foundation President Dr. Chari Cohen is quoted in a powerful new story about hepatitis B in The New Yorker. You can read it here.

LiverCancerConnect

News and Updates

Current News

Behind the LEAP-012 Trial of Lenvatinib, Pembrolizumab, and TACE in HCC

Application value of different imaging methods in the early diagnosis of small hepatocellular carcinoma: a network meta-analysis

Current Treatment Paradigm and Approach to Advanced Hepatocellular Carcinoma

Current and emerging strategies for the prevention of hepatocellular carcinoma

Immunotherapy combinations consolidate uHCC 1L treatment

Significant Disparities in Hepatocellular Carcinoma Outcomes by Race/Ethnicity and Sociodemographic Factors

Gauging Risk for Liver Cancer: Hepatitis B Viral Load Might Be a Clue

The Influence of Residential Segregation, Urbanicity, and Population Density on Hepatocellular Carcinoma Incidence among a Low Socioeconomic Population

LI-RADS US Surveillance Version 2024 for Surveillance of Hepatocellular Carcinoma: An Update to the American College of Radiology US LI-RADS

Tislelizumab Pushes HCC Field Forward With 2024 NCCN Guideline Category 1 Recommendation

Identification of ETV5 as a prognostic marker related to epigenetic modification in pan-cancer and facilitates tumor progression in hepatocellular carcinoma

CheckMate 9DW Study Results and Use of Ipiimumab/Nivolumab in First- and Second-Line Treatment

Locoregional Therapies for Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis

New Algorithm Discerns Cancer Risk in Advanced Chronic Liver Disease

Prospective appraisal of clinical diagnostic algorithms for hepatocellular carcinoma surveillance in Chinese patients with chronic hepatitis B infection

Combination of Gene Therapy and Chemotherapy in a New Targeted Hybrid Nanosystem to Hepatocellular Carcinoma

Ongoing Research Could Help Define the Role of Immunotherapy in Earlier-Stage HCC

Impact of Food Insecurity on the Incidence of Hepatocellular Carcinoma

Addressing Disparities in Liver Cancer Care to Improve Access to First-Line Treatment for Minority and Underserved Populations with Hepatocellular Carcinoma

Isolation and identification of patient-derived liver cancer stem cells and development of personalized treatment strategies

ABK Biomedical Announces FDA IDE Stage 2 Approval for Route90, a Prospective, Multi-Center, Pivotal Study of Eye90 microspheres® in unresectable Hepatocellular Cancer

Application of nanotechnology in the treatment of hepatocellular carcinoma

Transforming the landscape of liver cancer detection and care

Nomogram for predicting early recurrence of hepatocellular carcinoma with narrow resection margin

Newly found liver cancer biomarkers could lead to early diagnosis via blood test

Unlocking the Potential of Phyto Nanotherapeutics in Hepatocellular Carcinoma Treatment: A Review

Projected epidemiological trends and burden of liver cancer by 2040 based on GBD, CI5plus, and WHO data

Deep learning for oncologic treatment outcomes and endpoints evaluation from CT scans in liver cancer

A new screening tool improves liver cancer detection

Preoperative Noninvasive Prediction of Recurrence-Free Survival in Hepatocellular Carcinoma Using CT-Based Radiomics Model

Evaluating the potential of off-the-shelf engineered mesenchymal stem cells for targeted Hepatocellular Carcinoma treatment: A multisite proof-of-concept study

Signature of immune-related metabolic genes predicts the prognosis of hepatocellular carcinoma

Novel Multivariable Risk Score Outperforms FIB-4 for Identifying Patients At Risk of HCC

Tempest Receives FDA Study May Proceed for Pivotal Phase 3 Trial of Amezalpat Combination Therapy for the Treatment of First-Line Hepatocellular Carcinoma

Eureka Therapeutics Tackling Advanced Hepatocellular Carcinoma With T-Cell Therapy ECT204 in Phase 1/2 ARYA-3 Clinical Trial

Adding Lenvatinib Plus Pembrolizumab to TACE Improves Survival in Intermediate-Stage Hepatocellular Cancer

Isoscopoletin inhibits hepatocellular carcinoma cell proliferation via regulating glycolysis-related proteins

The Changing Face of Hepatitis Delta Virus Associated Hepatocellular Carcinoma

Myeloid Therapeutics Announces SITC 2024 Oral Presentation on MT-303, the First in vivo GPC3 Targeting mRNA CAR in Human Studies for Advanced Hepatocellular Carcinoma (HCC)

Cross-sectional study on the diagnostic significance of plasma exosomal miRNAs in HBV-related hepatocellular carcinoma

The load of hepatitis B virus reduces the immune checkpoint inhibitors efficiency in hepatocellular carcinoma patients

Risk Score for Hepatocellular Cancer in Adults Without Viral Hepatitis or Cirrhosis

Hepatocellular carcinoma survival data highlight importance of early detection

New model predicts liver cancer risk in hepatitis B patients without cirrhosis

Combination strategies in advanced hepatocellular carcinoma: the CARES-310 trial

GALAD Score for the Diagnosis of Hepatocellular Carcinoma in Sub-Saharan Africa: A Validation Study in Ghanaian Patients

Role of Imaging in Screening for Hepatocellular Carcinoma

Aspirin Use and Risk of Hepatocellular Carcinoma in Hepatitis B

USP26: Key Driver in HBV-Induced Liver Cancer

Lucy Mathew, NP: The Importance of Liver Cancer Screening, Barriers to Surveillance

FDA Approves Genentech’s Tecentriq Hybreza, the First and Only Subcutaneous Anti-PD-(L)1 Cancer Immunotherapy

Overcoming disparities in hepatocellular carcinoma outcomes in First Nations Australians: a strategic plan for action

Progression patterns in patients with advanced hepatocellular carcinoma treated with local therapy, targeted drugs, and PD-1/PD-L1 inhibitors

MicroRNA-15a/16-1 Prevents Hepatocellular Carcinoma by Disrupting the Communication Between Kupffer Cells and Regulatory T Cells

Estrogen Induces LCAT to Maintain Cholesterol Homeostasis and Suppress Hepatocellular Carcinoma Development

Resection Surgery Leads to Improved Liver Cancer Survival

Associations between modifiable risk factors and hepatocellular carcinoma: a trans-ancestry Mendelian randomization study

Development and validation of a biomarker index for HCC treatment response

Carisma Therapeutics Announces Nomination of First In Vivo CAR-M Development Candidate for Hepatocellular Carcinoma Under Collaboration with Moderna

New Tool Could Spot Liver Cancer Early, Upping Survival

A novel single-cell model reveals ferroptosis-associated biomarkers for individualized therapy and prognostic prediction in hepatocellular carcinoma

Preoperative Antiviral Therapy and Long-Term Outcomes for Hepatitis B Virus-Related Hepatocellular Carcinoma After Curative Liver Resection: A Multicenter Analysis

Investigating Hepatitis B Virus-Related Hepatocellular Carcinoma Incidence

Hepatocellular carcinoma immune microenvironment and check point inhibitors-current status

Immunosuppressive tumor microenvironment and immunotherapy of hepatocellular carcinoma: current status and prospectives

UAB Medicine Podcast: Multi-Disciplinary Hepatocellular Carcinoma Clinic (HCC)

Clinical and Epidemiological Aspects of Hepatocellular Carcinoma at the Internal Medicine Department of Point “G” Teaching Hospital in Mali

Insights into Hepatocellular Carcinoma: From Pathophysiology to Novel Therapies

FPU2023- Targeting the microenvironment in liver cancer

Old Vaccine Potentially Treats Liver Cancer

AFP L3 and DCP strongly predict early hepatocellular carcinoma recurrence after liver transplantation

Telomerase-related advances in hepatocellular carcinoma: A bibliometric and visual analysis

3D Contrast-Enhanced Ultrasound in Diagnosing Participants with Liver Cancer Undergoing Stereotactic Ablative Radiotherapy

Adding Immunotherapy to Local Treatment Delays Liver Cancer Progression

Global burden of liver cirrhosis and other chronic liver diseases caused by specific etiologies from 1990 to 2019

RALDH1 Inhibition Shows Immunotherapeutic Efficacy in Hepatocellular Carcinoma 

Design, Synthesis, and Anti-Hepatocellular Carcinoma Evaluation of Sesquiterpene Lactone Epimers Trilobolide-6-O-isobutyrate Analogs

Computational-guided approach for identification of PI3K alpha inhibitor in the treatment of hepatocellular carcinoma by virtual screening and water map analysis

Targeting metalloproteases is a promising strategy to enhance immunotherapy responses by overcoming immune exclusion in hepatocellular carcinoma

Network-based pharmacology-based research on the effect and mechanism of the Hedyotis diffusa–Scutellaria Barbata pair in the treatment of hepatocellular carcinoma

Construction and validation of a novel lysosomal signature for hepatocellular carcinoma prognosis, diagnosis, and therapeutic decision-making

Long-term risk of hepatocellular carcinoma and hepatic decompensation after hepatitis B surface antigen seroclearance: a territory-wide cohort of 9,769 patients

Analysis of primary care electronic health record data of people living with hepatitis B virus: infection and hepatocellular carcinoma risk associated with socio-economic deprivation

β-Sitosterol suppresses hepatocellular carcinoma growth and metastasis via FOXM1-regulated Wnt/β-catenin pathway

Development of pre-clinical murine models for fibrolamellar hepatocellular carcinoma

A Review of Incidence and Related Risk Factors in the Development of Hepatocellular Carcinoma

Q&A: Causes of hepatocellular carcinoma ‘differ remarkably’ by race, ethnicity

Dr Kurz on Social Determinants of Health That Contribute to Disparities in Cancer Care

News Archive

What to Know About Late-Stage Liver Cancer as a Black Person

A Guide to the Stages of Liver Cancer

2023 Update of Indian National Association for Study of the Liver Consensus on Management of Intermediate and Advanced Hepatocellular Carcinoma: The Puri III Recommendations

Neoadjuvant Nivolumab/Ipilimumab Combo Elicits Responses, Safety in Resectable HCC

Clinical manifestation, staging and prognosis of hepatocellular carcinoma in Gambian patients

Incidence of Etiology-specific Hepatocellular Carcinoma: diverging trends and significant heterogeneity by race and ethnicity

NCCN 2023 Liver Cancer Guidelines for Patients

Gene mutations linked to drug-resistant liver cancer

Complementary and Alternative Medicine

A Novel Online Calculator Based on Serum Biomarkers to Detect Hepatocellular Carcinoma among Patients with Hepatitis B

Management of Hepatocellular Carcinoma

BAIAP2L2 is a Novel Prognostic Biomarker Related to Migration and Invasion of HCC and Associated with Cuprotosis

Advancing the Care of Advanced HCC – A Hepatologist’s Perspective

Novel Use of Artificial Intelligence Shows Promise to Improve HCC Detection

Molecular and Clinical Features of Hepatocellular Carcinoma in Patients with HBV-HDV Infection

Genentech’s Tecentriq Plus Avastin Reduced the Risk of Cancer Returning in People With Certain Types of Adjuvant Liver Cancer in a Phase III Study

New 3D ultrasound may improve accuracy of liver cancer treatment 

Review of insights into the success and failure of systemic therapy for liver cancer

REACH-B Score for Hepatocellular Carcinoma

Minimally-invasive surgical options for liver cancer and liver tumors, and other options from the multidisciplinary team from Johns Hopkins (Video)

About Herbs, Botanicals, and Other Products (from Memorial Sloan Kettering Cancer Center)

Four Liver Cancer Treatment Advances 

Pan Tumor Clinical Trial Is Actively Recruiting to Investigate the Effects of Nivolumab When Given Under the Skin With or Without rHuPH20. Learn more! 

Assessing the Risk of HCC for Hepatitis B Treatments

Study Uncovers New Treatment Approaches for Liver Cancer Patients

NUS Scientists Discover New Clues to Liver Cancer Progression

Cancer survivors: Managing your emotions after cancer treatment

Researchers Identify a New tsRNA in Blood to Improve Liver Cancer Diagnosis

Case 3: Novel Frontline Combination Strategies for Unresectable HCC (Video)

What Gastroenterologists Need to Know About New Guidelines on Systemic HCC Therapy

Bringing Early Cancer Detection to the Masses

The Cancer Experience Registry is an online survey that allows people facing cancer to share their experiences, identify the issues that impact their life, and help them understand their experiences.

Dr. Gish talks about the importance of liver cancer surveillance and the blood work and imaging involved in regular monitoring - all in less than 2 minutes (Video)

What Cancer Survivors Should Know About Their Mental Health

Antiviral therapy improves survival among elderly patients after hepatectomy for hepatitis B virus (HBV)–related hepatocellular carcinoma (HCC)

AstraZeneca’s immunotherapy tremelimumab has secured its first FDA approval and is to be sold under the brand name Imjudo

FDA approves a combination of the immunotherapy drugs durvalumab (Imfinzi®) plus the experimental drug tremelimumab for people with unresectable hepatocellular cancer, the most common type of liver cancer

Evidence Grows for Avoiding Biopsy in Hepatocellular Carcinoma

New Guidelines Clarify Use of Systemic Therapy in Advanced HCC

After FDA Evaluation, BMS Withdraws Opdivo For Liver Cancer Treatment in Patients Previously Treated with Sorafenib in the U.S.

FDA Grants “Orphan Drug” Designation to Chemotherapeutic Uttroside-B for Use in Patients with HCC. The drug is in pre-clinical testing.

COVID-19: What People With Cancer Need to Know (Cancer.net, June 2020)

FDA Approves Atezolizumab Plus Bevacizumab for Patients With Unresectable or Metastatic Hepatocellular Carcinoma 

Atezolizumab Combination Improves Survival in HCC (Cancer Letter, May 2020)

U.S. FDA Approves Opdivo® (Nivolumab) + Yervoy® (Ipilimumab) for Patients with Hepatocellular Carcinoma Previously Treated with Sorafenib

U.S. Food and Drug Administration (FDA) Has Granted Breakthrough Device Designation to the Elecsys® GALAD Score to Help Diagnose HCC

FDA Has Approved Cabozantinib (CABOMETYX, Exelixis, Inc.) for Patients with Hepatocellular Carcinoma Who Have Been Previously Treated with Sorafenib

DNA Search Finds People Resistant to Liver Disease. Can We Mimic This Effect with a Drug? Regeneron and Alnylam Pharmaceutical to Partner  

Newly Discovered Anti-Cancer Protein LHPP Prevents Uncontrolled Proliferation of Cancer Cells in the Liver and May Serve as a Biomarker for the Diagnosis & Prognosis of Liver Cancer 

New Point-of-Care Ultrasound Tool May Aid Detection of Liver Stiffness in Obese Patients

Phase II Trial of GT90001 Plus Nivolumab Enrolls First Patient with Advanced HCC

Treatment of Hepatocellular Carcinoma in Sub-Saharan Africa: Challenges and Solutions

Kintor Initiates Dosing in Phase II Hepatocellular Carcinoma Therapy Trial

How Have Hepatocellular Carcinoma Treatments Improved?

Neoadjuvant Immunotherapy for Resectable Hepatocellular Carcinoma

Hepion Pharmaceuticals Receives FDA Orphan Drug Status Designation for Rencofilstat for the Treatment of HCC

Perioperative Opdivo Alone, in Combination with Yervoy, Safe for Patients with HCC

Omega Therapeutics Announces FDA Clearance of IND Application for OTX-2002, First Omega Epigenomic Controller, for MYC Driven Hepatocellular Carcinoma

AACR Report Finds Racial and Ethnic Minorities Continue to Shoulder a Disproportionate Burden of Cancer

Cabozantinib Plus Atezolizumab in Advanced Hepatocellular Carcinoma and the Role of Adjuvant Antiviral Therapy

Phase III Trial of Cabozantinib and Atezolizumab vs Sorafenib in Advanced Hepatocellular Carcinoma

Elevar Therapeutics and Hengrui Pharma Announce Camrelizumab Plus Rivoceranib Significantly Prolonged Overall Survival and Progression-Free Survival in Patients With Unresectable Hepatocellular Carcinoma (Phase III Trial)

New Study Shows Options for Older Patients With Liver Cancer

Novartis and BeiGene have announced new data from a phase 3 trial that shows tislelizumab demonstrated non-inferior overall survival (OS) compared to sorafenib in patients with previously untreated, unresectable hepatocellular carcinoma

Dr Reddy’s Laboratories announces the launch of Dr Reddy’s Sorafenib Tablets, USP, 200 mg, a therapeutic generic equivalent of Nexavar (sorafenib) Tablets in the US market following the approval by the US Food and Drug Administration

JW Therapeutics announces the initiation of phase I clinical study of JWATM204 in patients with advanced hepatocellular carcinoma

The International Liver Cancer Network (ILCN), of which HBF is a member, released a white paper promoting increased effort to improve prevention, early detection and access to care for liver cancer.

Cancer Burden Facing Asian Americans Partly Caused By Racism